Literature DB >> 821169

Doxycycline in serum and bronchial secretions.

B J Hartnett, G E Marlin.   

Abstract

The concentration of doxycycline hydrochloride was measured in serum and bronchial secretions in five patients with chronic bronchitis receiving doxycycline orally in normal therapeutic dosage for seven days (200 mg day 1, 100 mg days 2 to 7). After the loading dose of 200 mg, serum concentrations ranged between 5-40 and 3-45 mug/ml (mean 4-33 mug/ml) at 3 hours, declining to between 2-28 and 1-21 mug/ml (mean 1-71 mug/ml) at 23 hours. The mean serum levels for days 2 to 7 were 2-15, 1-79, and 1-38 at 3, 8, and 23 hours respectively. There was considerable individual variability and a wide range of concentrations of doxycycline in the sputum (0-07 to 2-10 mug/ml, mean 0-34 mug/ml). During the course of treatment there was a progressive increase in sputum levels and sputum/serum concentration ratios. There was no correlation between sputum concentration and degree of purulence. The clinical efficacy of doxycycline does not appear to be related to sputum concentration, although the progressive increase in sputum doxycycline levels may be relevant in preventing recurrence of acute infection when the drug is administered as long-term prophylactic therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 821169      PMCID: PMC470376          DOI: 10.1136/thx.31.2.144

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  15 in total

1.  The bacteriology of chronic bronchitis.

Authors:  J R MAY
Journal:  Lancet       Date:  1953-09-12       Impact factor: 79.321

2.  Amoxycillin levels in sputum, serum, and saliva.

Authors:  S M Stewart; I M Anderson; G R Jones; M A Calder
Journal:  Thorax       Date:  1974-01       Impact factor: 9.139

3.  Ampicillin levels in sputum, serum, and saliva.

Authors:  S M Stewart; M Fisher; J E Young; W Lutz
Journal:  Thorax       Date:  1970-05       Impact factor: 9.139

4.  Amoxycillin in the treatment of chronic non-tuberculous bronchial infections.

Authors:  J R May; A Ingold
Journal:  Br J Dis Chest       Date:  1972-07

5.  The penetration of doxycycline, oxytetracycline and minocycline into sputum.

Authors:  D MacCulloch; R A Richardson; G K Allwood
Journal:  N Z Med J       Date:  1974-10-09

6.  Treatment of acute exacerbations in chronic bronchitis.

Authors:  W R Aitchison; I W Grant; J C Gould
Journal:  Br J Clin Pract       Date:  1968-08

7.  Experiences with doxycycline in the management of acute respiratory tract infections.

Authors:  P Jacobs; R Robinson
Journal:  S Afr Med J       Date:  1969-02-22

8.  Comparison of in vitro activity and clinical pharmacology of doxycycline with other tetracyclines.

Authors:  J E Rosenblatt; J E Barrett; J L Brodie; W M Kirby
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966

9.  Treatment of acute exacerbations of chronic bronchitis in general practice.

Authors:  J Bennion-Pedley
Journal:  Br J Clin Pract       Date:  1969-07-07

10.  Tetracycline levels in bronchial secretions.

Authors:  M J Campbell
Journal:  J Clin Pathol       Date:  1970-07       Impact factor: 3.411

View more
  9 in total

Review 1.  Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Sinusitis, bronchitis, and mycoplasmal pneumonia.

Authors:  G A Pankey
Journal:  Bull N Y Acad Med       Date:  1978-02

3.  Plasma and sputum erythromycin concentrations in chronic bronchitis.

Authors:  G E Marlin; P R Davis; J Rutland; N Berend
Journal:  Thorax       Date:  1980-06       Impact factor: 9.139

4.  Pharmacokinetics of doxycycline in adults with cystic fibrosis.

Authors:  Paul M Beringer; Heather Owens; Albert Nguyen; Debbie Benitez; Adupa Rao; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

5.  Penetration of piperacillin into bronchial mucosa and sputum.

Authors:  G E Marlin; K R Burgess; J Burgoyne; G R Funnell; M D Guinness
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

6.  Serum, saliva, and sputum levels of metronidazole in acute exacerbations of chronic bronchitis.

Authors:  D Siegler; C M Kaye; S Reilly; A T Willis; M G Sankey
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

7.  Pharmacokinetics and tissue localization of doxycycline polyphosphate and doxycycline hydrochloride in the rat.

Authors:  G Michel; J Mosser; J Olle
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

8.  A Tet-Off gene expression system for validation of antifungal drug targets in a murine invasive pulmonary aspergillosis model.

Authors:  Yutian Peng; Hua Zhang; Min Xu; Man-Wah Tan
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

9.  Antibiotic treatment of chronic bronchitis.

Authors:  D T Hughes
Journal:  J R Coll Physicians Lond       Date:  1979-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.